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INTRODUCTION
The Ewing sarcoma family of tumors (ESFT) is derived from
cells of neural crest origin, probably postganglionic parasympa-
thetic primordial cells, based on their ability to synthesize
acetylcholine transferase [1]. The incidence is about three per
million children younger than 15 years, and these tumors account for
about 2% of all childhood malignancies. Soft tissue sarcomas are
derived from mesenchymal cells that normally mature into muscle,
fat, fibrous tissue, bone, and cartilage [2]. Rhabdomyosarcomas
derived from cells that normally develop into skeletal muscle are the
most common form of sarcoma in children and are the third most
common extracranial solid tumor in childhood. The incidence is
about 4.5 per million children, and there are about 250 new cases
per year in the United States. About two-thirds occur in children
6 years old or younger.
Positron-emission tomography (PET) using [18F]fluorodeoxy-
glucose (FDG) is useful for detection, staging, and monitoring a
variety of tumors in adults [3], including melanoma, head and neck
tumors, bronchogenic carcinoma, lymphoma, colon cancer, and
others. As pediatric malignancies are much less common, the
experience applying FDG PET in the management of childhood
cancers is limited [4–8]. The purpose of this study was to review our
12-year experience using this technique in children and young
adults with sarcomas to determine the uptake of FDG in childhood
sarcomas and the utility of FDG PET imaging in the staging and
restaging of children and young adults with sarcomas.
METHODS
FDG PET scans in 25 patients (46 scans) acquired over 12 years
were analyzed retrospectively. Images were analyzed by two
reviewers independently without knowledge of clinical details or
results of other imaging studies. Final clinical diagnosis was based
on biopsy, follow-up imaging, or clinical course. After a trans-
mission scan for attenuation correction, images were acquired
beginning 50 min after intravenous injection of 7–17 mCi FDG/
1.7 m2 of body surface area, depending on the emission acquisition
protocol in use at the time of the study. Images were obtained on a
Siemens CTI 931, Siemens Exact, or Siemens HRþ PET scanner.
Two-dimensional images were acquired, reconstructed by filtered
back projection in earlier studies, and ordered segmentation in later
studies. Sites of abnormal uptake were considered as focal
accumulations greater than surrounding background not explained
by normal organ uptake. Only standard uptake value (SUV) max is
reported since that value is the most reproducible among the SUV
options. SUVs could not be determined on tumors that did not
contain elevated concentrations of FDG nor on scans stored on
computer systems that are no longer operational.
Patients
There were 9 males and 16 females aged 2–24 years at the time
of diagnosis, with a median age of 10 years. Sixteen patients (64%)
had ESFT, including 11 with Ewing sarcoma (3 of whom were
mentioned in a previous report [4]) and 5 with primitive neuro-
ectodermal tumor. Nine patients (36%) had rhabdomyosarcoma
(5 embryonal and 4 alveolar). Nine patients were studied at initial
diagnostic staging (staging, 9 scans); 20 patients were studied as part
of subsequent restaging (16 patients, 37 scans) which includes scans
while still on treatment (11 patients, 23 scans), scans after the
end of therapy (7 patients, 13 scans), or scans at the time of relapse
(1 patient, 1 scan).
Fifteen patients had one scan performed, five patients two scans,
three patients three scans, one patient four scans, and one patient
eight scans. Follow-up time ranged from 4 to 186 months, with a
median follow-up time of 24 months. Scans were obtained between
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April 1991 and October 2002. Follow-up continued until March
2008. Initially, patients were examined at diagnosis to establish the
baseline metabolic activity. Subsequently, patients who underwent
PET scanning were selected based on clinical indications as
determined by the patient’s oncologist.
Sensitivity, specificity, positive predictive value, and negative
predictive value were calculated for PET performance based on
results of other scans, clinical follow-up, and biopsy results if
available. For this analysis, patients had to be at least 12 months
from initial diagnosis with concurrent studies that were performed
within 1 month of the FDG PET study. Two set of scans were




In nine of nine patients (seven EWS, one PNET, and one ERMS),
FDG PET imaging identified the primary tumor, and in eight of
those, it revealed all known metastases (Table I; Figs. 1 and 2). In a
single patient with EWS, 3-mm lung nodules identified on computed
tomography (CT) scanning were not evident on PET scanning,
probably because they were too small for the technical capability of
this scanning modality (Table I, Patient 2). These nodules resolved
after two cycles of chemotherapy. No false-positive lesions were
detected in any patient scans.
Restaging (During Treatment, After End of Therapy,
or at Relapse)
These include scans performed while still on treatment or after
the end of therapy or at the time of relapse (2–4). When patients had
scans done during Initial staging and Restaging it is listed as Initial
staging and Restaging. There were 37 scans acquired in 20 patients.
Table I describes the findings by patient and scan numbers.
Positive Scans
There were 20 positive scans in 10 patients (3 EWS, 2 PNET,
3 ARMS, and 2 ERMS). In five patients with EWS/PNET 8 positive
scans were recorded, whereas in five patients with ARMS/ERMS 12
positive scans were recorded, on 3 scans (two patients), false-
positive findings were detected. The first patient had a 12-mm
nodule in the right lower lobe that was proven on biopsy to be
pseudomonas infection. This patient with EWS remained disease
free 6 years after imaging and pathologic evaluation (Table I, Patient
17). The second patient with PNET had two false-positive scans.
The scan detected uptake in left inguinal lymph nodes 15 months
after completion of therapy (Table I, Patient 23) and remained
consecutively positive for 15 months before turning negative. The
patient remained in complete clinical remission for 5 years without
any symptoms, but subsequently had relapse in the left proximal
femur with no inguinal node involvement on the left side. The
patient was treated with chemotherapy and surgery and remained in
complete remission 27 months after salvage therapy.
Negative Scans
There were 17 negative scans in 10 patients (3 EWS, 3 PNET,
3 EMS, and 1 ARMS). In six patients with EWS/PNET 12 negative
scans were recorded, while in four patients with ARMS/ERMS
5 negative scans were recorded.
False-Negative Scans
Seven scans in four patients were classified as false negative. One
patient with EWS showed progression of disease in the femur
3 months after therapy despite lack of FDG uptake (Table I, Patient
7). In the second patient with ERMS, bladder activity interfered with
evaluation of a pelvic primary tumor (Table I, Patient 24). In a third
patient with PNET, 2-cm inguinal lymph nodes, subsequently
excised, did not accumulate FDG (Table I, Patient 22), and in a
fourth patient with ARMS, progressive disease in the pelvis did not
accumulate FDG (Table I, Patient 15).
True-Negative Scans
Seven patients had 12 true-negative scans (two EWS, three
PNET, and two ERMS). In five patients with EWS/PNET 10 true-
negative scans were recorded, while in two patients with ERMS
2 true-negative scans were recorded. These patients remained in CR
for 80–142 months. One of these patients remained in remission for
84 months after PET scan before relapse in the lungs. This patient
with EWS was alive with stable disease 2 months after imaging
evaluation (Table I, Patient 13).
Overall Performance of FDG PET for All Indications
To evaluate FDG PET performance in pediatric and young adult
patients with sarcoma, we compared scanning results to CT or
biopsy as available. Off 46 scans in 25 patients, there were 25 true-
positive scans, 3 false-positive scans, 12 true-negative scans, and
6 false-negative scans. The sensitivity of the PET scan was 86%,
specificity 80%, positive predictive value 89%, and negative
predictive value 67%.
DISCUSSION
Our findings indicate that FDG PET is a useful imaging modality
for the diagnostic evaluation of primary and metastatic sarcomas. In
addition, the study provided important diagnostic information that
guided the management of individual patients as presented in this
report. Importantly, this imaging modality provided important
utility for both diagnosis and ongoing tumor monitoring.
In a previous report of FDG PET scanning for the imaging of a
variety of pediatric tumors at the time of presentation [4], we
suggested a potential role for FDG PET, but conclusions were
tempered by patient numbers and the preliminary nature of the
findings. This original report included seven patients with sarcomas:
three with Ewing sarcoma, and one each with rhabdomyosarcoma,
osteosarcoma, hepatic sarcoma, and angiomyosarcoma. The scans
indicated that most of the pediatric tumors we studied were quite
active metabolically and the information obtained was clinically
useful. As a result, we expanded the study, focusing on the more
common ESFT and rhabdomyosarcoma. However, not all patients
treated at our institution during the early time frame of this study
underwent PET scanning due to limited research funds, issues with
insurance reimbursement, and scanner availability. Because of this,
our focus changed to imaging patients for whom we could
subsequently determine the validity of the PET scan findings by
either tissue confirmation or sufficient follow-up and for whom a
Pediatr Blood Cancer DOI 10.1002/pbc
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clinical question was posed. As a result, our study represents more
than 11 years’ experience using PET in childhood sarcomas.
These findings complement the work of other investigators [8,9]
who have suggested a role for this imaging modality in other cancer
settings. In pediatric patients with sarcomas and other tumors,
Wegner et al. [8] found that PET led to altered management in 46/
175 pediatric oncology patients, including 4 patients with sarcomas.
The limitation of this study was that it was conducted by sending a
questionnaire to referring physicians, asking them if they thought
PET resulted in a change of management in their patients, even
though many of these PET scan results were verified. In a second
study by Ben Arush et al. [9], FDG PET was determined to be































































































































































































































































































































































































































































































































































































































































































Fig. 1. Patient 25: Initial staging and treatment monitoring. Fifteen-
year-old with embryonal rhabdomyosarcoma. The patient presented
with bone pain from widely metastatic disease. A primary tumor was not
found. FDG PET anterior maximal intensity projection images show
widespread skeletal disease at presentation, partial response at 2 months,
progressive disease at 4 months, and partial response at 6 months.
Supraclavicular uptake at presentation and 2-month follow-up is due to
metabolically active fat (brown adipose tissue).
Fig. 2. Patient 3: Initial staging. Fourteen-year-old girl with Ewing
sarcoma at presentation. Anterior maximal intensity projection image
(a) shows a large focus of irregular but markedly increased uptake in the
right abdomen extending medially into the right lower thorax. The right
kidney is displaced inferiorly. b: Transverse reconstruction through the
abdominal mass shows markedly increased uptake along the lateral and
inferior margins of the mass with decreased uptake centrally, consistent
with necrosis.
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valuable for the detection of local and regional lymph node
involvement in children with alveolar rhabdomyosarcoma, though it
was a very small study involving only three patients. Finally,
Hawkins et al. [10], investigating FDG PET in 36 adult and pediatric
patients with ESFT, determined that FDG PET uptake correlated
with histologic response and that semiquantitative comparison of
pre- and post-treatment scans yielded prognostic information.
Our study has important limitations. During the 12-year course
of our study, PET equipment and reconstruction algorithms
advanced considerably, especially with regard to hybrid imaging
using PET CT [11]. As a result, current technology and imaging
quality provide more confident distinction of normal sites of uptake
from disease and added sensitivity by assisting in the identification
of pathology [6,7,12–14]. As an example, McCarville et al. [7]
found FDG PET CT useful for locating the primary site of a
metastatic rhabdomyosarcoma; for identifying unusual and unsus-
pected metastatic sites; in monitoring response to chemotherapy,
radiation therapy, and radiofrequency ablation; and in evaluating
tumor resection sites postoperatively. In a recent review investigat-
ing the utility of FDG PET CT in the staging and restaging of
53 patients with Ewing sarcoma, it was determined that 21% more
lesions were detected using PET CT than with PET alone, yielding
higher sensitivity, similar specificity, and higher accuracy for PET
CT [15]. Thus, because of the superiority of hybrid imaging over
PETalone, our results may underestimate the value of the technique
when accompanied by CT scanning for both attenuation correction
and lesion localization. In support of this argument, the study by
Gyorke et al. [14] determined that FDG PET was less sensitive than
CT for detecting pulmonary metastases in ESFT. Similarly, in
patients with soft tissue and bone sarcomas, Iagaru et al. [12,13]
showed that FDG PET CT had high sensitivity for the detection of
disease but lagged behind dedicated CT for the detection of
pulmonary metastases. In fact, our only false-negative finding in the
nine patients studied at diagnosis was the lack of detectable FDG
uptake in small pulmonary metastases.
Our patients were studied at various times during clinical course
on protocols available at the time of presentation. Our image
reviewers did not have access to clinical data, other imaging
studies, or the indication for the study. Thus, the PET scan was
interpreted without the clinical and correlative radiographic
information that is available in routine clinical interpretation
sessions; thus, this analysis probably underestimates the incremen-
tal value provided. To avoid overestimating the value of FDG PET
studies during treatment, several studies were classified as false
negative, although convincing proof of disease at the time the study
was performed was not present. In one patient, diffuse uptake in a
femur mimicked bone marrow recovery, although it ultimately
proved to be tumor. Magnetic resonance imaging showed
multiple lesions that would have resulted in change in interpretation
that had been made available to the interpreting physicians. The
FDG PET scan of Patient 9 became negative during treatment, and
other imaging studies confirmed the response. No further PET
studies were obtained, but the patient did suffer progressive disease
4 months later. Patient 8 was studied for the first time during therapy
at a time when other studies indicated a therapeutic response.
Unfortunately, a distended bladder precluded adequate evaluation
of the pelvis. The studies of Patients 15 and 24 were negative,
although the patients suffered progressive disease. A false-
positive finding of FDG uptake in a lower extremity was shown to
represent a benign osseous lesion on correlative imaging. Uptake
in benign osseous lesions has subsequently been reported in
many children undergoing FDG PET CT for evaluation of
malignancies [16].
Especially useful is the long-term follow-up of seven patients
with true-negative scans, followed up for as long as 12 years. In
those patients, the lack of FDG uptake confirmed the eradication of
malignancy.
We did not use the semiquantitative SUV for analysis either at
the time the images were acquired or at the time of this analysis. In
several of our patients, SUV could not be determined, either because
metabolically inactive foci of tumor could not be identified on PET
alone or because tumor was disseminated in the bone marrow and no
distinct focal area of abnormal uptake was evident for analysis.
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 3. Patient 14: Restaging of local-regional disease at relapse.
Eighteen-year-old with relapsed rhabdomyosarcoma. Transverse (a),
sagittal (b), and coronal (c) images of the FDG PET scan show a focus of
markedly increased uptake corresponding with a soft tissue mass (d) on
CT scan underlying the left fifth metatarsal.
Fig. 4. Patient 14: Restaging for distant disease at relapse. Non-
attenuation corrected transverse image of the chest (a) and posterior
coronal whole body image (b) show many foci of abnormal uptake in the
lung, not previously detected. The soft tissue lesion in the left foot is
present at the bottom of (b).
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Although not applicable to this series, SUV under carefully
controlled conditions may have prognostic information and may
be useful for determining response to therapy [5,10,17,18].
Nonetheless, SUVs are influenced by many factors, including
fasting state, time from injection to imaging, method of recon-
struction, and partial volume issues, all of which require stand-
ardization for meaningful interpretation [19].
Other less commonly used tracers may also be valuable for
investigating the pathophysiology of pediatric sarcomas. These
include the cellular proliferation marker FLT, hypoxia markers such
as F-MISO, and amino acids including tyrosine [20–23]. Because of
the neuroendocrine origin of EFST and their ability to synthesize
choline acetyltransferase [1], tracers of the cholinergic nervous
system could be valuable [24].
In summary, we have found FDG PET useful in the staging and
management of EFST and rhabdomyosarcomas in children. Further
studies are currently under way to systematically evaluate the utility
of the technique in greater numbers of children and being treated on
similar or identical protocols. We anticipate that advances in
technology and refinement of FDG PET and FDG PET CT
techniques will further aid in the management of children and
young adults with ESFT and rhabdomyosarcomas.
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